Combination of antihypertensive drugs from a historical perspective

Blood Pressure

Volumn 14, Issue 2, 2005, Pages 72-79

  Van Zwieten, Peter A ^a   Farsang, Csaba ^b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE PLUS METOPROLOL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIDAZOLINE DERIVATIVE; IMIDAZOLINE I1 RECEPTOR BLOCKING AGENT; IMIDAZOLINE I1 RECEPTOR STIMULATING AGENT; LABETALOL; LACIDIPINE; LOSARTAN; METOPROLOL; MOXONIDINE; NIFEDIPINE; PERINDOPRIL; RILMENIDINE; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL PLUS VERAPAMIL; UNCLASSIFIED DRUG; VERAPAMIL;

ANTIHYPERTENSIVE ACTIVITY; CLINICAL TRIAL; DIABETIC HYPERTENSION; DISEASE CONTROL; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG POTENTIATION; EDITORIAL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; ETHNIC DIFFERENCE; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LOW DRUG DOSE; MALIGNANT HYPERTENSION; META ANALYSIS; MONOTHERAPY; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; HISTORY, 20TH CENTURY; HUMANS; HYPERTENSION;

EID: 18444370869     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/08037050510008922     Document Type: Editorial

References (35)

1. Van Zwieten PA, Farsang C. Interactions between antihypertensive agents and other drugs. Blood Press. 2003;12: 351-352 (ESH Newsletter No. 17).
2. Van Zwieten PA, Farsang C. Beneficial combinations of two or more antihypertensive agents. Blood Press. 2004;13:62-63 (ESH Newsletter No. 18).
3. Guidelines subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines in the management of hypertension. J Hypertens. 1999;17:151-183.
4. Guidelines subcommittee. 2003 European Society of Hypertension-European society of cardiology guidelines for the management of arterial hypertension. J Hypertens. 2003;21:1011-1053.
5. The sixth report of Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure. Arch Intern Med. 1997;157:2413-2416.
6. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA. 2003;289:2560-72. Epub 14 May 2003. Erratum in JAMA. 2003;290:197.
7. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288: 2988-2997.
8. Mancia G, Grassi G. Combination treatment in antihypertensive drug trials. Cardiovasc Drugs Ther. 1997;11: 517-518.
9. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST). A randomized clinical trial. JAMA. 2003;290:2805-2816.
10. Brown MJ, Cruickshank JK, Dominiczak AF, MacGregor GA, Poulter NR, Russell GI, et al.; Executive Committee, British Hypertension Society. Better blood pressure control: How to combine drugs. J Hum Hypertens. 2003;17:81-86.
11. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet. 1990;335:827-838.
12. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet. 2002;359:995-1003.
13. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet. 2004;363:2022-2031.
14. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New Engl J Med. 2001;345:861-869.
15. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al.; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
16. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345: 870-878.
17. Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet. 2003;362:767-771.
18. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet. 2003;362:767-771.
19. Krum H, Carson P, Farsang C, Maggioni AP, Glazer RD, Aknay N, et al. Effect of valsartan added to background ACE-inhibitor therapy in patients with heart failure: Results from ValHeFT. Eur J Heart Failure. 2004;6:937-945.
20. SHEP Cooperative Research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA. 1991;265:3255-3264.
21. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350: 757-764.
22. (a) Liu L, Wang JG, Staessen JA for the Systolic Hypertension in China (Syst-China) Collaborative Group. Comparison of active treatment and placebo for older patients with isolated systolic hypertension. J. Hypertens. 1997;16:1823-1829.
23. Fitzgerald JD. B-adrenoreceptor antagonists. In: van Zwieten PA, editor. Handbook of hypertension, vol. 3. Amsterdam: Elsevier, 1984. p. 249-306.
24. Appel LJ. The verdict from ALLHAT - Thiazide diuretics are the preferred initial therapy for hypertension. JAMA. 2002;288:3039-3042.
25. Dahlöf B, Hosie J. Antihypertensive efficacy and tolerability of a new once-daily felodipine-metoprolol combination compared with each component alone. The Swedish/UK Study Group. Blood Press. 1993;1 Suppl:22-29.
26. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palu C, et al.; European Lacidipine Study on Atherosclerosis investigators. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation. 2002;106:2422-2427.
27. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GB, Miller ME, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation. 2000;102: 1503-10.
28. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356:366-372. Erratum in Lancet. 2000;356:514.
29. (a) Agabiti Rosei E, Dal Palu C, Leonetti G, Magnani B, Pessina A, Zanchetti A. Clinical results of the Verapamil in Hypertension and Atherosclerosis Study. J Hypertens. 2000;15:1337-1344.
30. Lonn E, Yusuf S, Dzavik V, Doris C, Yi Q, Smith S, et al.; SECURE Investigators. Effects of ramipril and vitamine E on atherosclerosis. The study to evaluate Carotic Ultrasound changes in patients treated with Ramiprl and Vitamine E (SECURE). Circulation. 2001;103:919-925.
31. Ruilope LM, Ulsan L, Segura J, Bakris GL. Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes. J Hypertens. 2004;22:217-222.
32. Farsang C, Kawecka-Jaszcz K, Langan J, Maritz F, Zannad F. Antihypertensive effects and tolerability of candesartan cilexetil alone and in combination with amlodipine. Clin Drug Invest. 2001;21:17-23.
33. Burnier M. Angiotensin II type 1 receptor blockers. Circulation. 2001;103:904-912.
34. Farsang C, Lengyel M, Borbas S, Zorandi A, Dienes BS, on behalf of the VERITAS investigators. Value of rilmenidine therapy and its combination with perindopril on blood pressure and left ventricular hypertrophy in patients with essential hypertension (VERITAS). Curr Med Res Opin. 2003;19:205-221.
35. Mewezes Falcão L, van Zwieten PA. Current diagnosis and treatment in heart failure. Lisbon: Publ. Lidel; 2001. p. 207-222.